Listen

Add to my selection

TAGRISSO

Medicine - Posted on May 15 2025

Active substance (DCI)

osimertinib

history (7)

4/23/25

TAGRISSO (osimertinib) - Unresectable non-small cell lung cancer (NSCLC)

Summary of opinion Favourable opinion for reimbursement in “the treatment of adult patients with locally advanced, unresecta...

CAV :
54321

icône flèche
10/17/24

TAGRISSO (osimertinib) - Cancer du poumon

Autorisation d’accès précoce octroyée à la spécialité TAGRISSO (osimertinib) dans l'indication « en monothérapie dans le tra...

icône flèche
12/20/23

TAGRISSO (osimertinib) - Non-small cell lung cancer (NSCLC)

-

CAV :
54321

icône flèche
1/19/22

TAGRISSO (osimertinib) - Cancer bronchique non à petites cellules (CBNPC)

Key points Favourable opinion for reimbursement only in the adjuvant treatment after complete tumour resection and after adj...

CAV :
54321

icône flèche
3/20/20

TAGRISSO (osimertinib)

Key points Favourable opinion for reimbursement as monotherapy in the first-line treatment of adult patients with locally ad...

CAV :
54321

icône flèche
9/13/17

TAGRISSO (osimertinib), tyrosine kinase inhibitor

Substantial actual benefit and minor improvement compared with chemotherapy combining a platinum salt with pemetrexed in pat...

CAV :
54321

icône flèche

9/21/16

TAGRISSO (osimertinib), tyrosine kinase inhibitor

No clinical benefit demonstrated in the treatment of locally-advanced or metastatic non-small cell lung cancer with EGFR T79...

CAV :
54321

icône flèche

Technical information

ATC code

L01EB04

Manufacturer

ASTRAZENECA

Presentation

TAGRISSO 40 mg, comprimé pelliculé
30 plaquettes aluminium de 1 comprimé (CIP : 34009 300 476 4 4)

TAGRISSO 80 mg, comprimé pelliculé
30 plaquettes aluminium de 1 comprimé (CIP : 34009 300 476 5 1)

All our publications

Respiratory tract cancers